Leveraged, Inverse, and Commodity ETFs

Not suitable for all investors, these ETFs or other exchange traded products represent unique risks, including leverage, derivatives, and complex investment strategies. Learn more

DB Base Metals Double Long ETN
Change company Symbol lookup
Select an option...
BDDXF DB Base Metals Double Long ETN
BURL Burlington Stores Inc
TNEN True North Energy Corp
H Hyatt Hotels Corp
ACEL Accel Entertainment Inc
USLM United States Lime & Minerals Inc
BWEN Broadwind Inc
EQIX Equinix Inc
TXMD TherapeuticsMD Inc
ORC Orchid Island Capital Inc
Go


Based in United Kingdom
Company profile

Closing Price
$9.00
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
0

MacroGenics to Participate in Upcoming Investor Conference

4:01 pm ET May 17, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference in May 2022.

-- H.C. Wainwright Global Investment Conference. MacroGenics' President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate overview in Miami, FL, on Wednesday, May 25, 2022, at 11:30 am ET. Management will also participate in one-on-one meetings.

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days.

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

CONTACTS:
Chris James, M.D., Vice President, Investor Relations & Corporate Communications
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,  info@macrogenics.com

https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png

CONTACTS:
Chris James, M.D., Vice President, Investor Relations & Corporate Communications
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,  info@macrogenics.com

https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png

comtex tracking

COMTEX_407348472/2010/2022-05-17T16:01:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.